Physician
Mackinac Straits Health System INC
Mackinac Straits Health System INC was paid $2.87M by Medicaid between Jan 2018 and Dec 2024, across 94 billing codes. Its largest line is 99284, emergency room visit (serious) — 33% of everything it billed.
33Billing provider infoMACKINAC STRAITS HEALTH SYSTEM INC
SAINT IGNACE, MI 49781
SAINT IGNACE, MI 49781
33aNPI1124283502assigned 07/24/2008
33bProvider typeFamily Medicine Physician
28Total paid$2.87M
24GClaims93,842
24DCodes billed94
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Michigan
Rank by total paid#38 of 826
Median peer was paid$98K
This provider vs. median29×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,604 | $238K | |
| 2019 | 9,657 | $210K | |
| 2020 | 10,520 | $341K | |
| 2021 | 13,576 | $455K | |
| 2022 | 15,360 | $528K | |
| 2023 | 18,478 | $584K | |
| 2024incomplete | 15,647 | $515K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 33% | 3,715 | 3,379 | $946K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 3,816 | 3,621 | $613K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 9.0% | 1,963 | 1,786 | $258K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 319 | 293 | $125K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.1% | 3,411 | 3,251 | $117K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 2,632 | 734 | $106K |
| 96375 | Therapeutic injection; each additional sequential IV push | 3.2% | 2,028 | 1,610 | $92K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 608 | 459 | $86K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.9% | 2,215 | 2,137 | $83K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 553 | 541 | $55K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 1,004 | 952 | $49K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 890 | 740 | $36K |
82 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.0% | 4,225 | $29K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,715 | $27K |
| 80053 | Comprehensive metabolic panel | <1% | 9,008 | $26K |
| 80061 | Lipid panel | <1% | 2,894 | $23K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 9,616 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,282 | $21K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 110 | $21K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,223 | $20K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 462 | $15K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,561 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 215 | $13K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,731 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,242 | $9K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 68 | $9K |
| 84439 | <1% | 2,314 | $8K | |
| 82728 | <1% | 510 | $3K | |
| 81001 | <1% | 3,792 | $3K | |
| 83735 | <1% | 1,442 | $3K | |
| 82607 | <1% | 376 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 88 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 42 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 37 | $2K |
| 81025 | <1% | 1,540 | $2K | |
| 97161 | <1% | 28 | $2K | |
| 86140 | <1% | 1,591 | $1K | |
| 72110 | <1% | 15 | $967.08 | |
| 80306 | <1% | 375 | $942.82 | |
| 73030 | <1% | 26 | $780.48 | |
| 83550 | <1% | 175 | $756.33 | |
| 83540 | <1% | 231 | $753.20 | |
| 87070 | <1% | 191 | $714.72 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $686.73 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 42 | $652.33 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 100 | $638.73 |
| 85651 | <1% | 393 | $632.69 | |
| 86803 | <1% | 116 | $583.32 | |
| 73564 | <1% | 12 | $570.40 | |
| 83690 | <1% | 1,072 | $480.58 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 224 | $472.46 |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 39 | $461.11 |
| 87088 | <1% | 152 | $459.42 | |
| 86376 | <1% | 68 | $340.77 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $291.42 |
| 85610 | <1% | 266 | $258.87 | |
| 86800 | <1% | 55 | $250.12 | |
| 84481 | <1% | 51 | $246.89 | |
| 85027 | <1% | 152 | $215.94 | |
| 83880 | <1% | 29 | $211.55 | |
| 96127 | <1% | 13 | $210.47 | |
| 73610 | <1% | 13 | $196.53 | |
| 87806 | <1% | 12 | $193.44 | |
| 87077 | <1% | 44 | $129.91 | |
| 84153 | <1% | 13 | $128.52 | |
| 82150 | <1% | 537 | $127.10 | |
| 84145 | <1% | 45 | $102.60 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13 | $101.55 |
| 87186 | <1% | 29 | $101.29 | |
| 83605 | <1% | 187 | $95.92 | |
| 84484 | <1% | 465 | $72.99 | |
| 85730 | <1% | 59 | $54.87 | |
| 81002 | <1% | 25 | $38.72 | |
| 82550 | <1% | 230 | $37.44 | |
| 85379 | <1% | 38 | $7.51 | |
| 82553 | <1% | 73 | $6.50 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,436 | $5.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,377 | $4.70 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 789 | $4.70 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,729 | $1.85 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 1,095 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 346 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 28 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 13 | $0.00 |
| J3490 | Unclassified drugs | 0% | 22 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 325 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 108 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 362 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 216 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 45 | $0.00 |
| 82962 | 0% | 18 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 31 | $0.00 |
| 72170 | 0% | 13 | $0.00 | |
| 96376 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHEESEMAN, KAREN (CEO)